Charles River Laboratories International Inc. (CRL)
CRL trades on NYSE in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$299.02
-0.94% on the day
Market cap
$14.3B
Large cap
Revenue · 2025
$4.0B
-0.9% on 2024
Net income · 2025
-$144.3M
-3.6% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | CRL on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2000 |
| SEC CIK | 0001100682 |
| SEC industry code | Services-Commercial Physical & Biological Research |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.0B |
| Net income | -$144.3M |
| Operating income | $25.2M |
| Net margin | -3.6% |
| Operating margin | 0.6% |
| Revenue growth | -0.9% |
| Cash | $213.8M |
| Total assets | $7.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3ASR | S-3ASR | 2024-05-09 |
| Latest annual report | 10-K | 2026-02-18 |
| Latest quarterly / interim | 10-Q | 2026-08-05 |
| Latest current report | 8-K | 2026-09-24 |
| Latest proxy | DEF 14A | 2026-03-31 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +1.1% |
| 1 month | +11.2% |
| 3 months | +32.5% |
| Year to date | +52.2% |
| 1 year | +77.9% |
| From 52-week high | -2.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ICLR | ICON plc | $164.34 | -0.04% | $12.6B |
| MEDP | Medpace Holdings Inc. | $609.89 | -1.64% | $17.0B |
| INCY | Incyte Corp. | $108.62 | -2.46% | $22.0B |
| IQV | IQVIA Holdings Inc. | $260.68 | -0.58% | $42.9B |
| ABSI | Absci Corporation | $9.10 | -5.89% | $1.6B |
| OABI | OmniAb Inc. | $4.70 | -1.47% | $683.3M |
| NRC | NRC Health | $20.17 | -1.18% | $446.2M |
| MXCT | MaxCyte Inc. | $0.9643 | -3.08% | $99.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier